The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

Recruiting now · Not applicable

Conditions studied: Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation, Systemic Therapy

In brief

Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.

Key facts

Study ID

NCT06609850

Run by

Sun Yat-sen University

People needed

116

Starts

2024-10-01

Expected to finish

2028-10-30

Last updated by the study team

2024-12-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-75 years;
• RHCC diagnosed by imaging;
• intermediate-stage RHCC (two to three lesions which at least one was >3 cm in size or more than three tumors);
• the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
• absence of extrahepatic metastasis or macrovascular invasion;
• Child-Pugh class A or B;
• TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.
• life expectance >3 months;

You may not qualify if…

• under 18 years or over 75 years of age;
• primary intermediate-stage HCC;
• RHCC with more than six tumors, or single RHCC
• (5) RHCC >5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;

Where it is running

• Chinese PLA General hospital — Beijing, None Selected, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.